Inhibition of c-Myc in Rhabdomyosarcoma and Other Tumors
Author Information
Author(s): Marampon Francesco, Ciccarelli Carmela, Zani Bianca M
Primary Institution: Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
Hypothesis
Can the oncogenic phenotype in Rhabdomyosarcoma and non muscle-derived human tumors be blocked by disrupting the c-Myc pathway?
Conclusion
The study shows that targeting the c-Myc pathway through MEK/ERK inhibition can reverse the malignant phenotype in Rhabdomyosarcoma and other tumor cell lines.
Supporting Evidence
- MEK/ERK inhibitor U0126 reduces c-Myc expression and induces growth arrest in tumor cell lines.
- Direct inactivation of c-Myc by MadMyc chimera leads to growth arrest and myogenic differentiation.
- U0126 treatment abolishes anchorage-independent growth in Rhabdomyosarcoma cells.
Takeaway
Scientists found that blocking a specific pathway in cancer cells can stop them from growing and help them behave more like normal cells.
Methodology
The study used pharmacological MEK/ERK inhibition and direct inactivation of c-Myc in various tumor cell lines to assess growth and differentiation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website